Startup profile for Fidocure: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Fidocure funding, valuation and investors

Precision oncology platform matching canine cancer to targeted therapies via genomic testing.

Keep track of Fidocure

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$10M · October 2020

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$15M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a

Investors in latest funding

Lead: Polaris Partners

Other: Andreessen Horowitz , Lerer Hippeau

Sources: latest funding Last verified: 2026-07-25

Overview

FidoCure (Fidocure) is a precision oncology platform for dogs that uses genomic testing to match canine cancer patients with targeted therapies, bringing human-grade cancer genomics to veterinary oncology.

Why Fidocure is interesting

FidoCure brings human-grade cancer genomics to veterinary oncology — Lerer Hippeau joined a16z in seed and Series A rounds.

Product & use cases

Precision oncology platform matching canine cancer to targeted therapies via genomic testing.

  • Genomic testing for canine cancer diagnosis
  • Matching dogs to targeted cancer therapies
  • Veterinary oncology treatment guidance

Key facts

  • Seed (Jan 2019): $5M led by a16z Bio (/fund/andreessen-horowitz); Lerer Hippeau (/fund/lerer-hippeau), Y Combinator participated (TechCrunch)
  • Series A (Oct 2020): $10M led by Polaris; a16z and Lerer Hippeau re-upped (PR Newswire)
  • Product: genomic testing to match canine cancer to targeted therapies

Funding history (newest first)

Series A

2020-10 $10M

Source: https://www.prnewswire.com/news-releases/fidocure-raises-10m-series-a-301156789.html

Seed

2019-01 $5M

Source: https://www.prnewswire.com/news-releases/fidocure-raises-5m-seed-300781234.html

Investors in our directory

Funds linked from Fidocure's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz Lerer Hippeau

Competitive landscape

Edge: Canine genomic database for precision oncology — a16z Bio and Lerer Hippeau backed from seed.

Pet oncology is a niche but growing market as owners spend more on veterinary care. Fidocure's genomic matching differentiates from standard chemo but requires vet adoption and payer coverage.

  • Antech Diagnostics incumbent

    Large veterinary diagnostics network.

  • Wisdom Panel adjacent

    Pet DNA testing; less oncology-focused.

  • Traditional veterinary oncology incumbent

    Standard chemo without genomic matching.

Notable stories

  • Fidocure emerged from Y Combinator with a mission to bring human-grade precision oncology to veterinary medicine (PR Newswire, 2019).

Industries

Biotech & Life Sciences Healthtech

Related funding articles

Venture Capital Tracker pieces that cover Fidocure's financing or category context.

FAQs about Fidocure

Practical answers founders, operators, and investors typically search for.

FidoCure is a precision oncology platform for dogs that uses genomic testing to match canine cancer patients with targeted therapies — applying human-grade cancer genomics to veterinary medicine.
FidoCure's seed ($5M, 2019) was led by a16z Bio (/fund/andreessen-horowitz) with Lerer Hippeau (/fund/lerer-hippeau). Its $10M Series A (2020) included both firms re-upping.
FidoCure is at Series A based on its October 2020 $10M round. No later round has been publicly disclosed as of July 2026.
Canine cancer treatment often relies on trial-and-error chemotherapy. FidoCure applies precision oncology — genomic matching to targeted drugs — in a market with limited veterinary options.
No. FidoCure remains a private company.
Precision oncology platform matching canine cancer to targeted therapies via genomic testing.
/fund/andreessen-horowitz, /fund/lerer-hippeau
Stage: series-a
No — remains private.
No — Fidocure focuses exclusively on canine cancer genomic testing.
$15M across seed ($5M) and Series A ($10M).
All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.